Skip to main content
Top
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients

Authors: Heidi Cung, Mario J Aragon, Katherine Zychowski, Joe R Anderson, James Nawarskas, Carlos Roldan, Akshay Sood, Clifford Qualls, Matthew J Campen

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

Vascular disease is promoted by systemic inflammation that can arise from sites distal to the affected vessels. We sought to characterize the net inflammatory potential of serum from patients with coronary artery disease (CAD) using cultured endothelial cells as a cumulative biosensor.

Methods and results

Serum samples from CAD patients (N = 45) and healthy control subjects (N = 48) were incubated with primary human coronary artery endothelial cells at a 1:10 dilution for 4 h, followed by isolation of the cellular RNA. Alteration of inflammation-responsive elements (adhesion molecules and cytokines) was assessed by gene expression. Specific indicators included intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and interleukin-8 (IL-8). Additionally, the cytokine levels in serum samples from all subjects were quantified. Serum from CAD subjects induced greater endothelial ICAM-1, VCAM-1, and IL-8 expression compared to healthy control serum (p < 0.001 for each analysis). The three indicators of inflammatory potential (ICAM-1, VCAM-1, and IL-8 mRNA) trended independently of each other and also of serum inflammatory biomarkers. IL-8 expression correlated negatively with serum HDL levels but positively correlated with VLDL, plasminogen activator inhibitor-1 and C-reactive protein. Interestingly, serum levels of cytokines in CAD patients were not statistically different from healthy control subjects. A year of follow-up in a sub-group of CAD subjects revealed relatively stable measures.

Conclusions

As yet unidentified circulating factors in the serum of CAD patients appear to activate endothelial cells, leading to upregulation of adhesion molecules and chemokines. This cumulative assay performed well in terms of discriminating patients with CAD compared to healthy subjects, with greater range and specificity than specific inflammatory markers.
Literature
1.
go back to reference Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26. doi:10.1056/NEJM199901143400207.CrossRefPubMed Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26. doi:10.1056/NEJM199901143400207.CrossRefPubMed
2.
go back to reference Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, et al. Potential Mechanisms Linking Atherosclerosis and Increased Cardiovascular Risk in COPD: Focus On Sirtuins. Int J Mol Sci. 2013;14:12696–713. doi:10.3390/ijms140612696.CrossRefPubMedCentralPubMed Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, et al. Potential Mechanisms Linking Atherosclerosis and Increased Cardiovascular Risk in COPD: Focus On Sirtuins. Int J Mol Sci. 2013;14:12696–713. doi:10.3390/ijms140612696.CrossRefPubMedCentralPubMed
3.
go back to reference Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186:11–6. doi:10.1164/rccm.201203-0455PP.CrossRefPubMed Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186:11–6. doi:10.1164/rccm.201203-0455PP.CrossRefPubMed
4.
go back to reference Lahousse L, van den Bouwhuijsen QJ, Loth DW, Joos GF, Hofman A, Witteman JC, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med. 2013;187:58–64. doi:10.1164/rccm.201206-1046OC.CrossRefPubMed Lahousse L, van den Bouwhuijsen QJ, Loth DW, Joos GF, Hofman A, Witteman JC, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med. 2013;187:58–64. doi:10.1164/rccm.201206-1046OC.CrossRefPubMed
5.
go back to reference Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013;25:147–51. doi:10.1097/MEG.0b013e32835a58b1.CrossRefPubMed Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013;25:147–51. doi:10.1097/MEG.0b013e32835a58b1.CrossRefPubMed
6.
go back to reference Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case–control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–50. doi:10.1161/01.ATV.0000160613.57985.18.CrossRefPubMed Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case–control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–50. doi:10.1161/01.ATV.0000160613.57985.18.CrossRefPubMed
7.
go back to reference Barve S, Joshi-Barve S, Song Z, Hill D, Hote P, Deaciuc I, et al. Interactions of cytokines, S-Adenosylmethionine, and S-Adenosylhomocysteine in alcohol-induced liver disease and immune suppression. J Gastroenterol Hepatol. 2006;21 Suppl 3:S38–42. doi:10.1111/j.1440-1746.2006.04590.x.CrossRefPubMed Barve S, Joshi-Barve S, Song Z, Hill D, Hote P, Deaciuc I, et al. Interactions of cytokines, S-Adenosylmethionine, and S-Adenosylhomocysteine in alcohol-induced liver disease and immune suppression. J Gastroenterol Hepatol. 2006;21 Suppl 3:S38–42. doi:10.1111/j.1440-1746.2006.04590.x.CrossRefPubMed
8.
go back to reference McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, et al. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002;27:185–92.CrossRefPubMed McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, et al. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002;27:185–92.CrossRefPubMed
9.
go back to reference Liang YJ, Shyu KG, Wang BW, Lai LP. C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol. 2006;40:412–20. doi:10.1016/j.yjmcc.2005.12.008.CrossRefPubMed Liang YJ, Shyu KG, Wang BW, Lai LP. C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol. 2006;40:412–20. doi:10.1016/j.yjmcc.2005.12.008.CrossRefPubMed
10.
go back to reference Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, et al. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis. 2006;185:39–46. doi:10.1016/j.atherosclerosis.2005.01.057.CrossRefPubMed Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, et al. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis. 2006;185:39–46. doi:10.1016/j.atherosclerosis.2005.01.057.CrossRefPubMed
11.
go back to reference Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:6523–7.CrossRefPubMedCentralPubMed Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:6523–7.CrossRefPubMedCentralPubMed
12.
go back to reference Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397–408. doi:10.1016/j.jacc.2013.05.016.CrossRefPubMed Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397–408. doi:10.1016/j.jacc.2013.05.016.CrossRefPubMed
13.
go back to reference Channell MM, Paffett ML, Devlin RB, Madden MC, Campen MJ. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model. Toxicol Sci. 2012;127:179–86. doi:10.1093/toxsci/kfs084.CrossRefPubMedCentralPubMed Channell MM, Paffett ML, Devlin RB, Madden MC, Campen MJ. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model. Toxicol Sci. 2012;127:179–86. doi:10.1093/toxsci/kfs084.CrossRefPubMedCentralPubMed
14.
go back to reference Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107:2342–7. doi:10.1161/01.CIR.0000066691.52789.BE.CrossRefPubMed Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107:2342–7. doi:10.1161/01.CIR.0000066691.52789.BE.CrossRefPubMed
15.
go back to reference Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, et al. Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res. 2011;90:475–83. doi:10.1093/cvr/cvr032.CrossRefPubMed Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, et al. Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res. 2011;90:475–83. doi:10.1093/cvr/cvr032.CrossRefPubMed
16.
go back to reference Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, et al. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013;166:246–8. doi:10.1016/j.ijcard.2012.09.027.CrossRefPubMedCentralPubMed Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, et al. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013;166:246–8. doi:10.1016/j.ijcard.2012.09.027.CrossRefPubMedCentralPubMed
17.
go back to reference Robertson S, Colombo ES, Lucas SN, Hall PR, Febbraio M, Paffett ML, et al. CD36 mediates endothelial dysfunction downstream of circulating factors induced by O3 exposure. Toxicol Sci. 2013;134:304–11. doi:10.1093/toxsci/kft107.CrossRefPubMedCentralPubMed Robertson S, Colombo ES, Lucas SN, Hall PR, Febbraio M, Paffett ML, et al. CD36 mediates endothelial dysfunction downstream of circulating factors induced by O3 exposure. Toxicol Sci. 2013;134:304–11. doi:10.1093/toxsci/kft107.CrossRefPubMedCentralPubMed
18.
go back to reference Campen M, Robertson S, Lund A, Lucero J, McDonald J. Engine exhaust particulate and gas phase contributions to vascular toxicity. Inhal Toxicol. 2014;26:353–60. doi:10.3109/08958378.2014.897776.CrossRefPubMed Campen M, Robertson S, Lund A, Lucero J, McDonald J. Engine exhaust particulate and gas phase contributions to vascular toxicity. Inhal Toxicol. 2014;26:353–60. doi:10.3109/08958378.2014.897776.CrossRefPubMed
19.
go back to reference Heyward VH. Practical body composition assessment for children, adults, and older adults. Int J Sport Nutr. 1998;8:285–307.PubMed Heyward VH. Practical body composition assessment for children, adults, and older adults. Int J Sport Nutr. 1998;8:285–307.PubMed
20.
go back to reference Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. doi:10.1056/NEJMoa1107477.CrossRef Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. doi:10.1056/NEJMoa1107477.CrossRef
21.
go back to reference Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499–506. doi:10.1001/jama.2012.6571. Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499–506. doi:10.1001/jama.2012.6571.
22.
go back to reference Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717–29. doi:10.1016/j.jacc.2013.02.098.CrossRefPubMed Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717–29. doi:10.1016/j.jacc.2013.02.098.CrossRefPubMed
23.
go back to reference Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99:1706–13. doi:10.1016/j.amjcard.2007.01.062.CrossRefPubMed Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99:1706–13. doi:10.1016/j.amjcard.2007.01.062.CrossRefPubMed
24.
go back to reference Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–8.CrossRefPubMed Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–8.CrossRefPubMed
25.
go back to reference Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, Investigators CS. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2:1934–40. doi:10.1111/j.1538-7836.2004.01017.x.CrossRefPubMed Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, Investigators CS. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2:1934–40. doi:10.1111/j.1538-7836.2004.01017.x.CrossRefPubMed
26.
go back to reference Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–84.CrossRefPubMed Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–84.CrossRefPubMed
27.
go back to reference Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332–7. doi:10.1016/j.jacc.2005.06.088.CrossRefPubMed Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332–7. doi:10.1016/j.jacc.2005.06.088.CrossRefPubMed
28.
go back to reference Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost. 2006;96:660–4.PubMed Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost. 2006;96:660–4.PubMed
Metadata
Title
Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients
Authors
Heidi Cung
Mario J Aragon
Katherine Zychowski
Joe R Anderson
James Nawarskas
Carlos Roldan
Akshay Sood
Clifford Qualls
Matthew J Campen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0457-5

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.